Cardiac Biomarkers Market Size, Emerging Trends and Overview to 2024: Hexa Reports

Hexa Reports

Market Research Reports and Insightful Company Profiles

Cardiac Biomarkers Market Analysis, Share and Size,

Emerging Trends, Growth, Overview And Segment

Forecasts To 2024

The cardiac biomarkers market is expected to reach USD13.3 billion by 2024, according to a new report

by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth

during the forecast period from 2016 to 2024. Analysis of global market trends focuses on the increasing

demand for cardiac biomarkers owing to its increased adoption in cardiovascular disease diagnosis.

Furthermore, this growth is attributed to a majority of factors, such as the high prevalence of Acute

Coronary Syndrome (ACS), continual technological advancements in the development of cardiovascular

biomarkers, increasing number of new product launches by the key market players, rising demand for

point of care cardiac testing kits, along with the high specificity and sensitivity of these biomarkers in the

detection of cardiovascular diseases, especially acute myocardial infarction.

Browse Detail Report With TOC @

http://www.hexareports.com/report/cardiac-biomarkers-market/details

The cardiac biomarkers market has been classified by type into troponin, Creatine kinase-MB(CK-MB), Btype Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin,

and others. Troponin is a heteromeric protein and comprises cardiac troponin T & I, which are

abbreviated as cTnT & cTnI, respectively.

Hexa Reports

Market Research Reports and Insightful Company Profiles

The troponin biomarkers segment is expected to grow lucratively in the forecast period at a significant

CAGR. The diagnostic efficiency and specificity related to cardiac biomarker testing renders it a

universally gold standard test to diagnose cardiovascular disorders worldwide. The market by

application is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure,

and...